13G Filing: Sabby Capital and Arca Biopharma Inc. (ABIO)

Page 3 of 9 – SEC Filing

6.
SHARED VOTING POWER 111,6007.
SOLE DISPOSITIVE POWER08.
SHARED DISPOSITIVE POWER 111,6009.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 111,60010.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

[_]11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)0.9512.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO?

CUSIP No.
00211Y4071.
NAME OF REPORTING PERSONSSabby Management, LLC2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) [_]

(b) [X]

3.
SEC USE ONLY4.
CITIZENSHIP OR PLACE OF ORGANIZATIONDelaware, USANUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.
SOLE VOTING POWER06.
SHARED VOTING POWER 557,6527.
SOLE DISPOSITIVE POWER08.
SHARED DISPOSITIVE POWER 557,6529.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 557,65210.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

[_]11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Follow Oruka Therapeutics Inc. (NASDAQ:ORKA)